treatment scheme was aimed at inhibiting neovascularization; however, the drugs used can inhibit cancer cell growth by a number of mechanisms.
In a different treatment scheme, aimed to treat a variety of recurrent or progressive tumors, fenofibrate could not demonstrate similarly encouraging effects [2] .
Under which conditions can fenofibrate be effective?
In basic and clinical research, PPAR agonists are generally used to inhibit angiogenesis [1] , [2] , [3] .
However, it has been revealed that they can stimulate angiogenesis as well, using as models human cultured endothelial cells and mouse cornea [4] . It could be argued that cell type and microenvironment determine effects on angiogenesis, and can be determined by the cell and host composition of the preclinical study model.
Downstream targets of PPAR agonists can
have multiple effects on gene expression and cell physiology: The subject of PPAR ligands as anticancer drugs has been reviewed recently. Grabacka et al., note that PPARα activation can engage molecular interplay among SIRT1, AMPK, and PGC-1α [5] which could explain, at least in part, the encouraging results of the Peyrl et al., study (more on this topic in [6] ). In cultured cervical cancer cells, however, fenofibrate can induce mRNA for PPARα, PPARγ and superoxide dismutase 1, with tendency to decrease radiation sensitivity [7] . In different types of gastrointestinal cancer, PPAR activity above or below normal can affect tumor growth [8] [8] .
Interestingly, in a recent mechanistic study on chronic lymphocytic leukemia (CLL), inhibitors of PPARα and fatty acid oxidation enzymes increased glucocorticoid-mediated killing of CLL cells in culture.
The study authors noted a similar effect on mouse CLL xenografts, where immune-deficient mice could be rescued by combination of GCs and PPARα inhibition [9] . Breast cancer cells survive due to enhancement of NF-kB activity by glucocorticoids [19] . NF-kB may also be activated by PPARα in breast cancer initiating cells [20] . Activation of NF-kB facilitates plasmacytoma cell resistance to glucocorticoids and to inhibitors of Janus kinases, and enables the cells to grow in the absence of Interleukin-6 [21] . In acute leukemia activation of NF-kB was associated with glucocorticoid treatment failure in children [22] , and chemotherapy failure in adults [23] . In cell culture, persistent activation of NF-kB could protect Acute Myeloid Leukemia cells from proteasome inhibitor bortezomib [24] . agonists, they show hepatic peroxisome proliferation, h y p e r t r o p h y , h y p e r p l a s i a , a n d e v e n t u a l l y hepatocarcinogenesis; these effects are accompanied by a higher expression of inflammatory genes in rodent liver, in comparison to monkeys [25] . The inflammatory effects in mice, however, can be modulated by glucocorticoids, as there appears to be a synergy of PPAR and GR against inflammatory signals [26] [27]:
PPARα blocks glucocorticoid receptor-mediated transactivation but cooperates with liganded glucocorticoid receptor for transrepression on NF-kB [28] . As result, in mice with hyperinsulinemia through high-fat diet, activation of PPARα limits GC-induced Glc intolerance [28] .
A synergy of nuclear receptors against inflammatory mediators can have importance for leukemic cells that are resistant to glucocorticoids [29] ; such cells can be killed in vitro by proteasome in inhibitor with a gene expression signature enriched for the STAT3 signal pathway [30] . The clinically permitted exposure, however, to the proteasome inhibitor, is rather low [31] , and bone marrow cells may modulate STAT3 signals [32] . Interestingly, chronic treatment with fenofibrate inhibits STAT3 activation, and prevents the IL-6-induced gene expression in wild-type but not in PPARα-deficient mice [33] . Tissue-specific modulators of PPARα could be therefore effective, to interfere with selected targets of the glucocorticoids in cancer cells in vivo [34] . For types of tumor cells that cannot integrate fatty acid oxidation in their metabolism, even fenofibrate should be studied as part of the antineoplastic drug combination, including however preferably assays not only on the malignant cells, but also on the cells that form their niche. As described, the molecular endpoint targets of PPAR pathways are useful variables in the analysis of drug interactions at the level of cell culture. 
